CytomX Therapeutics, Inc.
NASDAQ:CTMXBiotechnology
-$0.03 today
- Market cap
- $409.85M
- Beta
- 2.09
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.33
Volume 4.39M
Average 4.99M
CTMX Operating Income
Profit from core operations after operating expenses, before interest and taxes.
CytomX Therapeutics, Inc.NASDAQ: CTMX
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income turns negative
Q1 FY2026 operating income was -$19.67M, compared with $22.62M a year earlier. Trailing-twelve-month operating income was -$64.66M.
Context
- Operating income amounted to 29.3% of revenue in FY2025, up 11.2 pp from a year earlier.
- Operating income increased in 2 of the last 3 fiscal years.
What to watch
Whether operating income reaches the consensus estimate from 5 analysts of -$53.82M (-140.6%) for the fiscal year ending Dec 2026, a step up from the -189.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$19.67M+29.6% QoQ
- Last fiscal yearDec 2025
- -$22.36M-189.5% YoY
- LTMMar 2026
- -$64.66M-279.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -187.0% | -1213.2% | -1026.3 pp |
| 1 year | -189.5% | -140.6% | +48.8 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (22.36M) USD
- Year-over-year change
- -189.5%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (22.36M) | -189.5% |
| FY2024 | 2024-12-31 | 25M | +485.5% |
| FY2023 | 2023-12-31 | (6.48M) | +93.6% |
| FY2022 | 2022-12-31 | (101.34M) | +12.7% |
| FY2021 | 2021-12-31 | (116.04M) | — |
Operating Income vs competitors
How CTMX compares with its peers on the latest reported figures
- CTMX's LTM Mar 2026 operating income of -$64.66M is the 5th highest of the 10 companies compared; the peer median is -$85.87M.
- Its year-over-year change of -279.8% is the lowest of 9, against a peer median of +27.8%.
- Operating income amounts to 181.9% of revenue for CTMX, versus a peer median of 149.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Aug 2026 | $289.66M | +208.4% | — | 41.3% | |
| LTM Sep 2026 | $44.15M | +162.5% | — | 16.6% | |
| LTM Jun 2024 | -$36.99M | — | — | 4534.8% | |
| LTM Mar 2026 | -$63.66M | +36.0% | — | 40.5% | |
| LTM Mar 2026 | -$64.66M | -279.8% | — | 181.9% | |
| LTM Mar 2026 | -$85.87M | +19.6% | — | 619.6% | |
| LTM Mar 2026 | -$115.08M | +54.0% | — | 115.5% | |
| LTM Mar 2026 | -$118.48M | +5.6% | — | 149.6% | |
| LTM Jun 2026 | -$216.08M | -69.5% | — | 205.8% | |
| LTM Sep 2026 | -$334.5M | -30.5% | — | 298657.1% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding CTMX) | -$85.87M | +27.8% | — | 149.6% | |
Competitors are the stored peer set for CTMX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 37.31M | 53.16M | 101.21M | 138.1M | 76.2M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 37.31M | 53.16M | 101.21M | 138.1M | 76.2M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 114.19M | 111.65M | 77.68M | 83.38M | 68.73M |
| Selling, General & Admin | 39.16M | 42.85M | 30.02M | 29.73M | 29.84M |
| Operating Expenses | 153.35M | 154.5M | 107.7M | 113.11M | 98.57M |
| Depreciation & Amortization | 2.71M | 2.44M | 2.18M | 1.77M | 1.38M |
| EBITDA | (113.16M) | (96.87M) | 5.5M | 33.86M | (15.75M) |
| EBITDA Margin | -303.3% | -182.2% | 5.4% | 24.5% | -20.7% |
| Operating Income | (116.04M) | (101.34M) | (6.48M) | 25M | (22.36M) |
| Operating Margin | -311.0% | -190.6% | -6.4% | 18.1% | -29.3% |
| Interest Income | 255K | 1.68M | 9.84M | 7.14M | 5.21M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 172K | 2.02M | 9.81M | 7.1M | 5.23M |
| Income Before Tax | (115.87M) | (99.32M) | 3.32M | 32.09M | (17.13M) |
| Pre-Tax Margin | -310.5% | -186.8% | 3.3% | 23.2% | -22.5% |
| Income Tax Expense | 0 | 0 | 3.89M | 224K | 238K |
| Net Income | (115.87M) | (99.32M) | (569K) | 31.87M | (17.37M) |
| Net Margin | -310.5% | -186.8% | -0.6% | 23.1% | -22.8% |
| EPS (Basic) | (1.26) | (1.48) | (0.01) | 0.38 | (0.15) |
| EPS (Diluted) | (1.26) | (1.48) | (0.01) | 0.38 | (0.15) |
| Weighted Avg Shares | 64.15M | 65.74M | 73.81M | 84.44M | 137.94M |
| Weighted Avg Shares (Diluted) | 64.15M | 65.74M | 73.81M | 84.75M | 137.94M |
CytomX Therapeutics, Inc.
NASDAQ:CTMX
Intrinsic Alpha fair value
Locked
Current Price
$1.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.